X4 Pharmaceuticals, Inc. - Common Stock — Bilan trimestriel (NASDAQ:XFOR) | MetaTrader

Afficher le graphique complet Full chart

Nouvelles

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

X4 Pharmaceuticals obtient l’approbation européenne pour son médicament contre le syndrome WHIM

Stifel réitère sa recommandation sur X4 Pharmaceuticals suite aux progrès de l’essai

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

X4 Pharmaceuticals à la conférence Leerink : virage stratégique vers l’hématologie rare

X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology

Guggenheim initie la couverture de X4 Pharmaceuticals avec une recommandation d’achat

Guggenheim initiates X4 Pharmaceuticals stock with buy rating